Healthcare / Medical DevicesTaipei Exchange
$10.95
-0.10 (-0.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-47.8M · quality 73.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$693M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.7%
↓Gross Margin
32.9%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-21.0%
FCF CAGR
—
FCF margin
-156.9%
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $30.4M · net income $-55.7M · FCF $-47.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $30.4M | $30.4M | $53.1M | $65.3M | $61.6M |
| Net Income | $-55.7M | $-55.7M | $-50.6M | $-45.3M | $-53.5M |
| EBITDA | $-55.5M | $-55.5M | $-34.4M | $-25.6M | $-36.6M |
| EPS | — | — | -0.88 | -0.85 | -0.99 |
| Gross Margin | 32.9% | 32.9% | 62.0% | 62.9% | 61.7% |
| Operating Margin | -289.0% | -289.0% | -121.8% | -82.7% | -104.4% |
| Net Margin | -183.1% | -183.1% | -95.2% | -69.4% | -86.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.04 | 0.02 |
| Current Ratio | 23.23 | 23.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-47.8M | $-47.8M | $-54.9M | $-41.9M | $-34.8M |
| Returns | |||||
| ROE | -10.7% | -10.7% | -8.9% | -11.9% | -12.6% |
| Valuation | |||||
| P/B | 1.33 | 1.33 | 2.25 | 4.01 | 2.06 |
| Growth & Yield | |||||
| Revenue Growth | -42.7% | -42.7% | -18.6% | 5.9% | — |
| EPS Growth | — | — | -3.5% | 14.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.88 → n/d
Residual
-25.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.